RE: Day 906 Apr 2021 15:33
I do tend to agree with Doc. Maltml, both of the points you make are also correct in my mind.
To help clarify, I looked at what Prof Nick Francis, Professor of General Practice at the University of Southampton, said on the completion of recruitment into its Phase II HT in January 2021 "We are excited to see whether we can detect important benefits from early use of inhaled interferon beta (SNG001) for COVID-19 in the home environment, in terms of resolution of symptoms, preventing hospitalisation, and reducing the burden of Long-COVID."
Reading this I have assumed that our nearest goal is confirming IF SNG001 reduces symptoms, preventing hospitalisation, and reducing the burden of Long-COVID. Importantly, I see our 2nd goal, in the longer term and in a study that I would expect to last at least a further 12-18 months, as looking at HOW SNG001 affects the long-Covid sufferer. So IMO it is 2 separate studies (If and How) .
I could be wrong but that's my thinking on it.